

#3  
20

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



Application of: Li et al.

Application Serial No: Unassigned

Group Art Unit: Unassigned

Filed: Concurrently herewith

Examiner: Unassigned

Title: **G-Protein Receptor HTNAD29**

Atty. Docket No.: PF191D1C1

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-BA listed on the attached Form PTO/SB/08A. A copy of each of references AY, AZ, and BA is enclosed.

Copies of references AA-AX were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/399,095, filed September 20, 1999, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of reference(s) AA-AX.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file


history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due. However, should the Patent Office determine otherwise, please charge any required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: February 28, 2002



Mark J. Hyman  
Attorney for Applicants

(Reg. No. 46,789)

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (240) 314-1224

Enclosures  
MJH/KM/rmr

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JC986 U.S. PTO  
 10/084206  
 02/28/02

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	Unassigned
				Filing Date	Concurrently herewith
				First Named Inventor	LI et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	PF191D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	AP	Hla et al., "An abundant Transcript Induced in Differentiating Human..." J. Biol. Chemistry 265(16):9308-9313 (1990)		
	AQ	Scott, JK et al., "Searching for peptide ligands with an epitope library", Science 27; 249(4967):386-390 (1990)		
	AR	Eva, C. et al., Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family", FEBS Letters 271:81-84 (1990)		
	AS	Ross, P. et al., "RTA, a candidate G protein-coupled receptor: Cloning, sequencing, and tissue distribution", Proc. Of Nat. Acad. Of Science, 87:3052-3056 (1990)		
	AT	Meyerhof, W. et al., "Molecular cloning of a novel putative g-protein coupled receptor expressed during rat spermiogenesis", FEBS Letters 284 (2):155-160 (1991)		
	AU	Oliveira, L. et al., "A common motif in G-protein-coupled seven transmembrane helix receptors", J. of Computer-Aided Mol. Design 7:649-658 (1993)		
	AV	Lee, N. et al., "Molecular Biology of G-protein-coupled receptors" DN&P 6(7):488-496 (1993)		
	AW	George, D. et al., "Current Methods in Sequence Comparison and Analysis", Macromolecular Sequencing and Synthesis, 127-149 (1988)		
	AX	Sambrook et al., "Molecular Cloning A Laboratory Manual", 3(2):16.2-16.30 and 17.3-17.28 (1989)		
	AY	Im, D et al., "Identification of a Molecular Target of Psychosine and Its Role in Globoid Cell Formation", J. of Cell Biology 153(2) 429-434 (2001)		
	AZ	Kyaw, H. et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene", Cell Biol. 17(6):493-500 (1998)		
	BA	Choi, JW. Et al., "Identification of a putative G protein-coupled receptor induced during activation-induced apoptosis of T cells", Cell Immunol. 168(1):78-84 (1996)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. PTO  
10/084206  
02/28/02

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	
				Unassigned	
				Filing Date	
				Concurrently herewith	
				First Named Inventor	
				LL et al.	
Group Art Unit				Unassigned	
Examiner Name				Unassigned	
Sheet	1	of	2	Attorney Docket Number	PF191D1C1

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	5,721,351		Levinson	02/24/1998	
	AB	6,084,083		Levinson	07/04/2000	
	AC	6,156,887		Levinson	12/05/2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AD	WO	92/01810		Lerner et al.	02/06/1992		
	AE	WO	93/07294		Konig et al.	04/15/1993		
	AF	WO	93/12134		President and Fellows of Harvard College	06/24/1993		
	AG	WO	94/05695		New York University	03/17/1994		
	AH	WO	96/27603		Millennium Pharm., Inc.	09/12/1996		
	AI	WO	98/32858		Schering Corporation	07/30/1998		
	AJ	WO	00/22131		Behan, et al.	04/20/2000		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>6</sup>
	AK	Swiss-Prot Accession No. P32250 (1993)			
	AL	GenBank Accession No. AA298823, "Thyroid Homo sapiens cDNA 5" (1997)			
	AM	GenBank Accession No. T87010, "Soares fetal liver speen INFLS Homo sapiens cDNA clone" (1995)			
	AN	GenBank Accession No. T86932, "Homo sapiens cDNA clone 115277 3" (1995)			
	AO	Libert et al. "Selective Amplification and Cloning of ..." Science 244:569-572 (1989)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.